Tech Company Financing Transactions

Indapta Therapeutics Funding Round

On 12/17/2024, Indapta Therapeutics raised $22.5 million in financing from Leaps by Bayer, Myeloma Investment Fund and Pontifax Venture Capital.

Transaction Overview

Company Name
Indapta Therapeutics
Announced On
12/17/2024
Transaction Type
Venture Equity
Amount
$22,500,000
Round
Undisclosed
Investors

Leaps by Bayer (Lead Investor) (Fabio Pucci)

Myeloma Investment Fund (Lead Investor)

Pontifax Venture Capital (Lead Investor)

RA Capital Management (Lead Investor)

Vertex Ventures HC (Lead Investor) (Lori Hu)

Proceeds Purpose
The company intends to use the funds to accelerate the clinical development of its differentiated allogeneic Natural Killer (NK) cell therapy.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Francisco, CA 94105
USA
Phone
Undisclosed
Website
www.indapta.com
Email Address
[email protected]
Overview
Indapta is a biotechnology company seeking to harness the natural power of the immune system to fight hematologic and solid cancers with our universal G-NK cell platform. Headquartered in San Francisco, Indapta was founded in 2017 by Guy DiPierro along with Ronald Martell and scientists at the University of California, Davis, and Stanford University.
Profile
Indapta Therapeutics LinkedIn Company Profile
Social Media
Indapta Therapeutics Company Twitter Account
Company News
Indapta Therapeutics News
Facebook
Indapta Therapeutics on Facebook
YouTube
Indapta Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chairman
Ronald Martell
  Ronald Martell LinkedIn Profile  Ronald Martell Twitter Account  Ronald Martell News  Ronald Martell on Facebook
Chief Executive Officer
Mark Frohlich
  Mark Frohlich LinkedIn Profile  Mark Frohlich Twitter Account  Mark Frohlich News  Mark Frohlich on Facebook
VP - Bus. Development
Guy Dipierro
  Guy Dipierro LinkedIn Profile  Guy Dipierro Twitter Account  Guy Dipierro News  Guy Dipierro on Facebook
VP - Bus. Development
Lori Kunkel
  Lori Kunkel LinkedIn Profile  Lori Kunkel Twitter Account  Lori Kunkel News  Lori Kunkel on Facebook
VP - R & D
Austin Bigley
  Austin Bigley LinkedIn Profile  Austin Bigley Twitter Account  Austin Bigley News  Austin Bigley on Facebook
VP - Regulatory Affairs
Elana Van Oudenaren
  Elana Van Oudenaren LinkedIn Profile  Elana Van Oudenaren Twitter Account  Elana Van Oudenaren News  Elana Van Oudenaren on Facebook

 

 

Browse more venture capital transactions:

Prev: 12/17/2024: eLstar Dynamics venture capital transaction
Next: 12/18/2024: BVNK venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.